首页> 外文期刊>Urologia internationalis >Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer
【24h】

Oncological Outcome and Value of Postoperative Magnetic Resonance Imaging after Focal High-Intensity Focused Ultrasound Therapy for Prostate Cancer

机译:前列腺癌术焦高强度超声治疗后术后磁共振成像的肿瘤术后和价值

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Focal therapy (FT) by high-intensity focused ultrasound (HIFU) is an emerging option for localized prostate cancer (PC). Due to the lack of long-term data, a close monitoring after FT is essential, but there are still uncertainties about the optimal follow-up regimen. Here we report on a series of FT-HIFU patients with the focus on oncological short-term outcome and the value of postoperative magnetic resonance imaging (MRI). Methods: We included 21 patients treated by FT-HIFU using the Focal One (R) device (EDAP TMS, France) between November 2015 and May 2018. PC localization was assessed by preoperative multiparametric MRI (mpMRI) and transrectal ultrasound-guided targeted and systematic biopsy. Oncological follow-up included prostate-specific antigen (PSA) development, mpMRI, control biopsies (targeted and systematic) of the treated and untreated areas and salvage treatment rate. Control mpMRI and control biopsy were performed after 6-12 months. Results: 15 patients (71.4%) were managed by focal ablation of a solitary lesion, while 6 patients (28.6%) underwent zonal tumor ablation. All patients underwent control mpMRI and biopsy. After a mean follow-up period of 11.7 months, cancer relapse was detected in 8 patients (38.1%), with 4 patients (19%) having infield recurrence. Postoperative mpMRI revealed 3 out of 4 infield PC relapses but missed 5 out of 7 outfield relapses. Clinically significant cancer recurrence was present in 1 patient (4.8%), which was missed by mpMRI. Posttreatment mpMRI had a sensitivity, specificity, positive and negative predictive value of 62.5, 92.3, 83.3 and 80.0%, respectively, for overall relapse detection based on patient level. Only 1 of the 8 recurrences was suspected based on PSA progression. 4 of the 8 patients with PC relapse (19%) underwent salvage therapy (2 patients by radical prostatectomy, 2 patients by salvage FT-HIFU). Conclusion: Postoperative mpMRI might play a valuable role during follow-up after focal HIFU therapy, particularly in terms of infield relapse detection. Irrespective of mpMRI results, the repeat biopsy regimen should incorporate systematic biopsy including cores of the treated and untreated prostate areas.
机译:简介:高强度聚焦超声(HIFU)的焦点治疗(FT)是局部前列腺癌(PC)的新出现选择。由于缺乏长期数据,FT至关重要后密切监测,但仍有关于最佳随访方案的不确定性。在这里,我们报告了一系列FT-HIFU患者,重点关注肿瘤的短期结果和术后磁共振成像(MRI)的价值。方法:我们在2015年11月和2018年5月间使用FT-HIFU(EDAP TMS)和2018年5月的FT-HIFU治疗21名患者。通过术前多游荧光MRI(MPMRI)和群体超声引导的PC定位评估PC定位系统活检。肿瘤学随访包括前列腺特异性抗原(PSA)的发育,MPMRI,对照治疗和未处理区域的控制活检(靶向和系统)和挽救治疗率。对照MPMRI和对照活检在6-12个月后进行。结果:15名患者(71.4%)通过突出病变来管理,而6例患者(28.6%)接受了肿瘤肿瘤消融。所有患者均接受了对照MPMRI和活组织检查。在平均随访期为11.7个月后,8名患者(38.1%)检测到癌症复发,4名患者(19%)具有蛋白质复发。术后MPMRI透露了4个内场PC中的3个,未错过7个Outfield中的5个。临床上显着的癌症复发存在于1名患者(4.8%)中,其被MPMRI遗漏。 PostTreatment MPMRI分别具有62.5,92.3,83.3和80.0%的敏感性,特异性,正负预测值,分别基于患者水平的整体复发检测。仅基于PSA进展疑似8个复发中的1个。 8名PC复发患者中的4例(19%)进行了救助治疗(由自由基前列腺切除术,2名患者进行救助FT-HIFU)。结论:术后MPMRI在局灶性HIFU治疗后随访期间可能在临床疗法后的随访中发挥着宝贵的作用,特别是在infield复发检测方面。不管MPMRI结果如何,重复活检方案应包含系统活检,包括治疗和未处理的前列腺区域的核心。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号